Recce has expertise in research and development of pharmaceutical drugs that kill germs. It has synthesised and patented RECCE antibiotics. The Company plans to undertake both the development of a production 'model', and the pre-clinical regulatory requirements of RECCE antibiotics designed for human use.

It is anticipated that RCE will list on the ASX during October 2015.